DOCSLIB.ORG

Softigel All Technologies Portfolio

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Softigel All Technologies Portfolio Softigel Product Catalogue Unique product formulations for an enjoyable consumer experience V 2.0 201807 www.softigel.com PROCAPS AT A GLANCE A leading Unparalleled Softgel Our Vertical We work Our major production Scientific Expertise: marketer Integration hand in hand Facilities are located in Developing more than of advanced-softgel & Flexibility with our customers Colombia, Brazil, 50 products related technologies gives us greater market and develop products Venezuela and per year reach & customer relevance that exceed their El Salvador expectations We employ over Our products are sold 5,000 people Devoted teams +100 formulation & distributed in over for client/market across 13 coutries scientists including 50 countries PhDs, MSCs and technicians www.softigel.com Softigel Products Catalogue 2018 OTC RX SUPPLEMENTS TABLE OF CONTENT PRODUCTS PRODUCTS Click on each section to access www.softigel.com Softigel Products Catalogue 2018 OTC Products Click on each section to access A B C D E G H I N P S T V www.softigel.com OTC products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Acetaminophen 500mg Non-Narcotic Analgesics Softgel Capsule RX products Acetaminophen 150mg/5ml Non-Narcotic Analgesics Syrup Acetaminophen + Caffeine 500mg + 50mg Non-Narcotic Analgesics Tablets Supplements Acetaminophen + Caffeine 250mg + 200mg Non-Narcotic Analgesics Softgel Capsule Acetaminophen + Chlorpheniramine + 250mg + 2.5mg Cold Preparations Softgel Capsule Dextromethorphan + Pseudoephedrine + 10mg + 30mg Acetaminophen + Chlorpheniramine + Phenylephrine 500mg + 2mg + 5mg Cold Preparations Softgel Capsule Acetaminophen + Lycasin 10g/100ml Non-Narcotic Analgesics Drops Acetaminophen + Phenylephrine + Caffeine + Cetirizine 500mg + 10mg + 30mg + 5mg Cold Preparations Softgel Capsule Acetaminophen + Pseudoephedrine 250mg + 30mg Cold Preparations Softgel Capsule + Chlorpheniramine + Dextromethorphan + 2.5mg + 10mg Acetaminophen + Pseudoephedrine Dextromethorphan 250mg + 30mg + 10mg Cold Preparations Softgel Capsule Ascorbic Acid (Vit C) 500mg Vitamin C Hard Capsule Ascorbic Acid (Vit C) 500mg Vitamin C Softgel Capsule Bromhexine 8mg Expectorants Softgel Capsule Back to home Bromhexine + Mint 8mg Expectorants Softgel Capsule OTC products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Bromhexine + Mint 4mg / 5ml Expectorants Syrup RX products Caffeine + Phenylephrine 30mg + 10mg Expectorants Softgel Capsule + Ibuprofen + Levocetirizine + 400mg + 2.5mg Supplements Calcium 600mg Calcium Supplements Tablets Calcium + Vitamin D 500mg + 300mg Calcium Supplements Tablets Vitamin A and D, including Cholecalciferol 2000UI Softgel Capsule combinations of the two Vitamin A and D, including Cholecalciferol 1000UI Softgel Capsule combinations of the two. Clotrimazole 100mg Gynaecological Antifungals Softgel Capsule Clotrimazole 1% Gynaecological Antifungals Cream Dextran + Hypromellose 1mg + 3mg/ml Ophtalmic Solution Drops Diclofenac + Aluminium 100mg + 200mg Anti-rheumatics, Non-steroidal Softgel Capsule Diclofenac Diethylammonium 0.954 g (1,16 % p/p) Anti-rheumatics, Non-steroidal Spray Diclofenac Diethylammonium 0.9547g/100ml Anti-rheumatics, Non-steroidal Spray Dimethicone 40mg Antacids, Antiflatulents Softgel Capsule Back to home Diphenhydramine 50mg Hypnotics & Sedatives Softgel Capsule OTC products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Drugs For Constipation - Stimu- RX products Docusate Calcium 240mg Softgel Capsule lant Laxatives Drugs For Constipation - Stimu- Docusate Sodium 100mg Softgel Capsule lant Laxatives Supplements Drugs For Constipation - Stimu- Docusate Sodium 200mg Softgel Capsule lant Laxatives Escin 20g Varicose Therapy, System Gel Cerebral and Peripheral Vaso- Ginkgo Biloba 40mg Softgel Capsule therapeutics Hedera Helix 50mg Expectorants Softgel Capsule Ibuprofen 200mg Non-Narcotic Analgesics Softgel Capsule Ibuprofen 400mg Non-Narcotic Analgesics Softgel Capsule Ibuprofen + Caffeine 200mg + 65mg Non-Narcotic Analgesics Softgel Capsule Ibuprofen + Caffeine 400mg + 65mg Non-Narcotic Analgesics G-Tabs Ibuprofen + Diphenhydramine 200mg + 25mg Non-Narcotic Analgesics Softgel Capsule Ibuprofen + Phenylephrine + Chlorpheniramine 200mg + 10mg + 1mg Cold Preparations Softgel Capsule Back to home Ibuprofen + Pseudoephedrine 200mg + 30mg Cold Preparations Softgel Capsule OTC products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Ibuprofen + Pseudoephedrine 400mg + 60mg Cold Preparations Softgel Capsule RX products Naproxen 275mg Non-Narcotic Analgesics Softgel Capsule Naproxen 250mg Non-Narcotic Analgesics Softgel Capsule Supplements Nystatin + Zinc Oxide 10.000.000UI + 20g Gynaecological Antifungals Cream Ectoparasiticides, Including Pinus Mugo Pumilio + Benzoic Acid 550 ml Household Spray Scabicides Ectoparasiticides, Including Pinus Mugo Pumilio + Benzoic Acid 400ml Household Spray Scabicides Ectoparasiticides, Including Pinus Mugo Pumilio + Benzoic Acid 50ml Household Spray Scabicides Ectoparasiticides, Including Pinus Mugo Pumilio + Benzoic Acid 200ml Household Spray Scabicides Simethicone 125mg Antacids Antiflatulents Softgel Capsule Soy Protein + Vitamin A + Ascorbic Acid (Vit C) 26g + 3200UI + 9mg + 500UI + + Vitamin D + Riboflavin (Vit B2) + Pyridoxine (Vit B6) 1mg + 0.3mg + 3mcg + 2mg + Powder + Cyanocobalamin (Vit B12) + Pantothenic Acid + Folic Acid 40mcg + 900mg + 150 mcg + + Calcium + Iodine + Iron + Phosphorus + Zinc 8mg + 750mg + 10mg / 100g Tramadol + Acetaminophen 37.5mg + 325mg Non-Narcotic Analgesics Softgel Capsule Back to home OTC products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form RX products Vitamin A + Cholecalciferol + Vitamin E + Ascorbic Acid (Vit 25000UI + 1250UI + 25UI + 160mg C) + Thiamine (Vit B1) + Riboflavin (Vit B2) + Pyridoxine (Vit + 5mg + 5mg + 5mg + 6mcg + Multivitamins with Minerals Softgel Capsule B6) + Cyanocobalamin (Vit B12) + Niciamide (Vit B3) + Folic 74mg + 250mcg + 6mg + 150mg Acid + Calcium Pantothenate + Calcium + Iron + 15mg Supplements Vitamin E + Selenium 400UI/50mcg Other Vitamins Softgel Capsule Back to home Softigel Products Catalogue 2018 RX Products Click on each section to access A B C D E F G H I K L M N O P Q R S T V Z www.softigel.com RX products º Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Acetaminophen + Codeine 325mg/30mg Narcotic Analgesics Softgel Capsule RX products Acetaminophen + Codeine 500mg/30mg Narcotic Analgesics Softgel Capsule Miotics And Antiglaucoma Acetazolamide 250mg Tablet Supplements Preparations Bone Calcium Regulators, Alendronate 70mg Bisphosphonates for osteo- Softgel Capsules porosis and related disorders Diabetes and nerve-related Alpha-lipoic acid 600mg Tablet symptoms of diabetes Amikacin 500mg/2 mL Aminoglycosides Injectable Aminophylline 240mg/10mL Respiratory Infections Injectable Respiratory, Urinary tract infections, meningitis, Ampicillin 1g Vial salmonellosis, and endocar- ditis. Respiratory, Urinary tract infections, meningitis, Ampicillin 500mg Vial salmonellosis, and endocar- ditis. Back to home RX products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Respiratory, Urinary tract RX products infections, meningitis, Ampicillin + sulbactam 1,5g Vial salmonellosis, and endocar- ditis. Supplements Ascorbic Acid (Vit C) + Iron + Zinc + Niacinamide (Vit B3) + 100mg + 5mg + 11,25mg + Cyanocobalamin (Vit B12) + Retinol (Vit A) + D-Panthenol 20mg + 6mcg + 8.500UI Multivitamins Pediatric Drops + Roboflavin (Vit B2) + Thiamine (Vit B1) + Vitamin D + + 4,9mg + 2,5mg + 3mg + Pyridoxine (Vit B6) 1.700UI + 1,5mg/ml Acetaminophen + Codeine 325mg/30mg Narcotic Analgesics Softgel Capsule Cholesterol And Triglyceride Atorvastatin 40mg Softgel Capsule Regulating Preparations Cholesterol And Triglyceride Atorvastatin 10mg Softgel Capsule Regulating Preparations Cholesterol And Triglyceride Atorvastatin + Omega 10mg + 84% Unigel Regulating Preparations Cholesterol And Triglyceride Atorvastatin + Omega 20mg + 84% Unigel Regulating Preparations Anticholinergic or Atropine 1 mg/1 mL Injectable antiparasympathetic Azithromycin 200mg/5ml Macrolides & Similr Type Suspension Back to home RX products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Azithromycin 500mg Macrolides & Similr Type Tablet RX products Aztreonam 1g Infections Vial Betacarotene + Ascorbic Acid (Vit C) + Vitamin E + Riboflavin 6,6mg + 200mg + 50UI + 5mg Supplements (B2) + Zinc + Copper + Selenium + Lutein + Zeaxanthin + + 24mg + 2mg + + 20mcg + Eye Tonics and Eye Vitamins Softgel Capsule Manganese 2mg + 2mg + 5mg Betahistine 16mg All Oth.Therapeutic Prd Tablet Betahistine 24mg All Oth.Therapeutic Prd Tablet Betahistine 8mg All Oth.Therapeutic Prd Tablet Betamethasone 4mg/ml Plain Corticosteroids Injectable Betamethasone 8mg/2ml Plain Corticosteroids Injectable Acetaminophen + Codeine 325mg/30mg Narcotic Analgesics Softgel Capsule Betamethasone Dipropionate + Betamethasone Sodium 5mg + 2mg/ml Plain Corticosteroids Prefilled Syringe Phosphate Betamethasone Dipropionate + Betamethasone Sodium 5mg + 2mg/ml Plain Corticosteroids Vial Phosphate Betamethasone Dipropionate + Betamethasone Sodium 4mg Plain Corticosteroids Injectable Phosphate Back to home RX products Back to: OTC products Pharmaceutical Molecule Concentration Indication Form Betamethasone Dipropionate + Betamethasone Sodium RX products 8mg Plain Corticosteroids Injectable Phosphate Betamethasone
Load more

Recommended publications
  • Softgels' Clear Advantages
    DEEPDIVE REPORT March 2019 naturalproductsinsider.com Softgels’ Clear Advantages Report brought to you by DEEPDIVE REPORT Softgels’ Clear Advantages Contents Market snapshot ..................................................................................... 3 Consumer appeal .................................................................................... 4 Softgel history .......................................................................................... 6 Advantages of softgels ........................................................................... 7 How softgels are made .......................................................................... 9 Softgel challenges and solutions .......................................................11 Oxidation ...........................................................................................11 Consumer experience .......................................................................12 Dietary considerations ......................................................................12 Shelf stability ....................................................................................14 Bioavailability ....................................................................................14 Innovative developments .....................................................................16 Copyright © 2019 Informa Exhibitions LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the
    [Show full text]
  • Prescription Advantage Drug Exclusions
    February 23, 2006 Dear Prescription Advantage Member: This letter is to inform you about changes to your Prescription Advantage coverage because of the new Medicare prescription drug coverage that began on January 1, 2006. Since this drug coverage will be available, Prescription Advantage will provide supplemental coverage for prescription drug purchases of members who are eligible for Medicare. For all members, with or without Medicare, Prescription Advantage will only cover classes of drugs that Medicare has not excluded from coverage. We have determined that you have taken one or more of the prescription drugs listed on the second page of this letter, which Medicare has excluded from coverage. As of March 31, 2006, Prescription Advantage will no longer cover these drugs. We recommend that you speak to your doctor regarding this change in drug coverage as he or she can most appropriately advise you of any viable alternatives or substitutions that are available to you. Your doctor is the most qualified person to determine which prescription drugs are suitable for you. If you have any questions, please call Customer Service (toll free) at 1-800-AGE-INFO (1-800- 243-4636) or TTY for the deaf and hard of hearing at 1-877-610-0241. Sincerely, Prescription Advantage Commonwealth of Massachusetts Executive Office of Health and Human Services Executive Office of Elder Affairs Prescription Advantage 1-800-AGE-INFO (1-800-243-4636) TTY: 1-877-610-0241 www.800ageinfo.com 3/9/2006 Page 2 of 3 Alkabel-sr tablet Fioricet tablet Phenazopyridine plus
    [Show full text]
  • Oral Drug Delivery: Formulation Selection Methods & Novel Delivery Technologies
    ORAL DRUG DELIVERY: FORMULATION SELECTION METHODS & NOVEL DELIVERY TECHNOLOGIES OUTSTANDING ISSUE SPONSOR www.ondrugdelivery.com “Oral Drug Delivery: Formulation Selection Approaches CONTENTS & Novel Delivery Technologies” This edition is one in the ONdrugDelivery series of pub- No Longer a Hit-or-Miss Proposition: lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Once-Daily Formulation for Drugs with ery, and is supported by industry leaders in that field. pH-Dependent Solubility Gopi Venkatesh, Director of R&D & Anthony Recupero, EDITORIAL CALENDAR 2011: Senior Director, Business Development June: Injectable Drug Delivery (Devices Focus) Aptalis Pharmaceutical Technologies 4-8 July: Injectable Drug Delivery (Formulations Focus) September: Prefilled Syringes A possible approach for the desire to innovate October: Oral Drug Delivery Brian Wang, CEO & Dr Junsang Park, CSO November: Pulmonary & Nasal Drug Delivery (OINDP) GL PharmTech 10-13 December: Delivering Biotherapeutics SUBSCRIPTIONS: COMPANY PROFILE - To arrange your FREE subscription (pdf or print) to Mayne Pharma International 14-15 ONdrugDelivery, contact: Guy Furness, Publisher From Powder to Pill: A Rational Approach to T: +44 (0) 1273 78 24 24 E: [email protected] Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development SPONSORSHIP/ADVERTISING: Molecular Profiles Ltd 16-19 To feature your company in ONdrugDelivery, contact: Guy Furness, Publisher LiquiTime* Oral Liquid
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • A Randomized and Observer Blinded Comparison of Continuous Femoral
    a & hesi C st lin e ic n a l A f R Möller. J Anesthe Clinic Res 2011, 4:1 o e l s e a Journal of Anesthesia & Clinical DOI: 10.4172/2155-6148.1000.277 a n r r c u h o J ISSN: 2155-6148 Research Case Report Open Access A Randomized and Observer Blinded Comparison of Continuous Femoral Block and Fascia Iliaca Compartment Block in Hip Replacement Surgery Thorsten Möller1,2, Sabine Benthaus2, Maria Huber2, Ingrid Bentrup2, Markus Schofer3, Leopold Eberhart2, Hinnerk Wulf2 and Astrid Morin2* 1Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany 2Department of Anesthesiology and Critical Care Medicine, Philipps-University Marburg, Marburg, Germany 3Department of Orthopedy and Rheumatology, Philipps-University Marburg, Marburg, Germany Abstract Background: Techniques, analgesic effects and functional outcome of continuous femoral nerve and fascia iliaca compartment blocks were compared in patients undergoing hip replacement surgery. Methods: 80 patients were enroled in this randomized and observer-blinded study. 40 patients received a femoral nerve catheter with a stimulating catheter (FEM group) and 40 patients a fascia iliaca compartment catheter (FIC group). Before surgery, the catheters were placed. 50 mL prilocaine 1% was administered and a continuous infusion of ropivacaine 0.2% was maintained for 24 hours. Postoperative pain management with non-steroidal anti- inflammatory agents was standardized during the first 24 hours. No bolus application of a local anesthetic was allowed during this period. Intravenous opioide PCA with piritramide (comparable with morphin) was provided for 24 hours, and the patients were instructed to titrate their pain below a level of visual analogue scale of 3.
    [Show full text]
  • Safety Data Sheet
    SDS Number 110529 Approved/Revised 23-Jun-2008 Version 14 Material AGENERASE SOFTGEL CAPSULES SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING space Material AGENERASE SOFTGEL CAPSULES space Synonym(s) AGENERASE CAPSULES * AGENERASE SOFTGEL CAPSULES 50 MG * AGENERASE SOFTGEL CAPSULES 150 MG * AMPRENAVIR, FORMULATED PRODUCT space Company Name GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK space UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response space GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US space US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response . 2. COMPOSITION / INFORMATION ON INGREDIENTS space Ingredients CAS # Percent EC-No. AMPRENAVIR 161814-49-9 6 to 7.4 NON-HAZARDOUS INGREDIENTS Unassigned 92.6 to 94 3. HAZARDS IDENTIFICATION space Fire and Explosion Expected to be non-combustible. space Health Caution - Pharmaceutical agent. May produce adverse effects on the development of human offspring. Possible effects of overexposure in the workplace include: diarrhoea; nausea; tingling; vomiting; rash. Health effects information is based on hazards of components. Handling this product in its final form presents minimal risk from occupational exposure. space Environment No information is available about the potential of this product to produce adverse environmental effects. 4. FIRST-AID MEASURES space Ingestion Never attempt to induce vomiting.
    [Show full text]
  • Continuous Pericapsular Nerve Group Block for Postoperative Pain
    Fujino et al. JA Clinical Reports (2021) 7:22 https://doi.org/10.1186/s40981-021-00423-1 CASE REPORT Open Access Continuous pericapsular nerve group block for postoperative pain management in total hip arthroplasty: report of two cases Takashi Fujino1* , Masahiko Odo1, Hisako Okada1, Shinji Takahashi2 and Toshihiro Kikuchi1 Abstract Background: Total hip arthroplasty (THA) is one of the surgical procedures associated with severe postoperative pain. Appropriate postoperative pain management is effective for promoting early ambulation and reducing the length of hospital stay. Effects of conventional pain management strategies, such as femoral nerve block and fascia iliaca block, are inadequate in some cases. Case presentation: THA was planned for 2 patients with osteoarthritis. In addition to general anesthesia, continuous pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block were performed for postoperative pain management. Numerical rating scale (NRS) scores measured at rest and upon movement were low at 2, 12, 24, and 48 h postoperatively, suggesting that the treatments were effective for managing postoperative pain. The Bromage score at postoperative days (POD) 1 and 2 was 0. Conclusion: Continuous PENG block and LFCN block were effective for postoperative pain management in patients who underwent THA. PENG block did not cause postoperative motor blockade. Keywords: Pericapsular nerve group (PENG) block, Continuous peripheral nerve block, Total hip arthroplasty, Peripheral nerve block Background reported that it was more effective for managing postop- Total hip arthroplasty (THA) is associated with signifi- erative pain associated with THA than conventional cant postoperative pain [1]. Opioids are typically used peripheral nerve blocks [6].
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • From Molecule to Dose Form Bioavailability Toolkit to Fast Track Development Introduction
    contents introduction 2 part one: Connecting the 4 Dots in Drug Delivery part two: The Bioavailability 8 Toolbox part three: The Toolbox of 2025 16 part four: Delivering Change 21 from molecule to dose form bioavailability toolkit to fast track development introduction When it comes to drug formulation challenges, there trend and the key to succeed in this competitive is no one-size-fits-all solution. landscape. The leading evidence of this trend includes more direct-to-consumer advertising and a The 3rd annual drug delivery landscape survey* recent patient focused drug development initiative confirms that bioavailability, safety, efficacy by the FDA to gather the patient’s perspective and solubility are the top challenges faced by on their condition and available treatments. formulation scientists. The pharmaceutical and Interestingly, survey data shows that although biopharmaceutical industries have to overcome not the industry has identified the value of patient- only formulation challenges but also the business centric drug design, it has not been very successful challenges of bringing a product successfully to in applying it. For instance, to successfully apply market. The survey participants, a vast majority of patient-centric design, the drug product should be whom are Formulation Scientists and R&D Managers, adapted as per the patient’s preference at earlier indicated that development time, selecting the stages of drug development to avoid high costs at appropriate drug delivery platform, budget and late stages, a practice which is not very common in choosing the right external partner are the top the industry. Also, when asked to rate the significant business challenges.
    [Show full text]
  • Product Information
    ATROPINE INJECTION BP (Atropine sulfate monohydrate) 1. NAME OF THE MEDICINE Atropine sulfate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Atropine Injection BP is a sterile, isotonic, preservative free solution containing 600 microgram of atropine sulfate monohydrate in 1 mL or 1.2 mg of atropine sulfate monohydrate in 1 mL. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Preanaesthetic medication to reduce salivary secretions and bronchial secretions to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability concurrent administration with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects. 4.2 Dose and Method of Administration Atropine Injection may be given by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Injection should not be added to any IV infusion solutions for administration. Atropine Injection contains no microbial agent. It should be used only once and any residue discarded. Cardiopulmonary resuscitation The usual adult dose is 0.4 - 1 mg IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved. The total dose should not exceed 2 mg. Page 1 of 11 The usual paediatric dose is 0.02 mg/kg (maximum single dose 0.5 mg) IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved.
    [Show full text]
  • Capsule Robot: a Theranostic Approach
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 10 October 2019 Review Article Capsule Robot: A Theranostic Approach Pradnya Palekar Shanbhag*, Tejal Gawade, Prerna Patil and Priyanka Deshmukh Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Affiliated to University of Mumbai, India *Corresponding Author: Pradnya Palekar Shanbhag, Head and Professor, Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada,Received: Navi September Mumbai, 11, Affiliated 2019 ; Published: to University September of Mumbai, 27, India. 2019 DOI: 10.31080/ASPS.2019.03.0407 Abstract Increasing development in healthcare systems and availability of efficient miniaturized components or systems that are economic has led to profound scope for research in many new fields. Capsule robot was one such fictional idea that turned into factual reality because of use of applicative miniaturized components. Initially capsule robots were developed for endoscopic applications. These travel inside the gastrointestinal tract and thus capture images of the gastrointestinal tract and related areas. Later, capsule robots were developed to be used as the unique tool to construct micron and sub-micron sized drug delivery systems for target delivery and treatment. This article highlights on various aspects of capsule robots in diagnosis and therapy of various disorders and diseases, togetherKeywords: called Capsule theranostic Robot; approachEndoscopy; in Diagnosis;drug delivery Therapy systems. Introduction The rising demand for non invasive methodology for diagnosis controlled manner, Drug Delivery System (DDS) capsule endoscopy was designed. There are quite a number of research studies using rine type capsules which travel inside the body were used for en Microelectromechanical Systems (MEMS) for evaluating the drug and treatment led to the invention of capsule robots.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]